---
pmcid: PMC7934554
image_filename: 13058_2021_1408_Fig4_HTML.jpg
figure_link: /pmc/articles/PMC7934554/figure/Fig4/
number: Fig. 4
figure_title: ''
caption: Pre-treatment immune pathway scores in patients with partial response (PR)
  and progressive disease (PD). a Antigen presentation score. b Cytokine and chemokine
  signaling score. c Immune infiltration score
article_title: An open-label, pilot study of veliparib and lapatinib in patients with
  metastatic, triple-negative breast cancer.
citation: Erica M. Stringer-Reasor, et al. Breast Cancer Res. 2021;23:30.

doi: 10.1186/s13058-021-01408-9
journal_title: 'Breast Cancer Research : BCR'
journal_nlm_ta: Breast Cancer Res
publisher_name: BioMed Central

keywords:
- PARP inhibitors
- DNA repair
- Synthetic lethality
- Targeted therapy
- Triple-negative breast cancer

---
